Initially, I believe you are correct. In the next fiscal year, Medicare should negotiate a lower price per dose ($15.50) and we can start to see what the insurance carriers really are more frightened of, lawsuits from patients that develop opiate use disorders because they could not obtain Suzetrigine because they were denied coverage, or the cost (maybe $3.00 per 50 mg) of Medicare negotiated pricing.
I have never been at the accounting end of medicine so I have no clue which way it will fall. What I do know is that the high initial pricing will lead to many additional drugs of the Na 1.8 volt class being developed and cleared which will completely change market dynamics - eventually. Hope most of us can wait.